MedTrace Logo

123 I-FP-CIT SPECT Prescriptions for Parkinsonian Syndromes

NCT05698784 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 723

Last updated 2023-02-03

No results posted yet for this study

Summary

123I-FP-CIT SPECT (DaTSCAN®) allows to detect presynaptic dopamine neuronal denervation. It is recommended to differentiate neurodegenerative parkinsonism from secondary parkinsonian syndromes or from essential tremor, and to distinguish patients with suspected dementia with Lewy bodies and those with other subtypes of dementia. The aim of this retrospective study was to evaluate the relevance of 123I-FP-CIT SPECT prescriptions, the profile of prescribers and the evolution of the prescription rate over a ten-year period.

Conditions

  • Parkinson

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de la Guadeloupe

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Bertrand DEGOS, MD, PhD · Hopital Avicenne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05698784 on ClinicalTrials.gov